Clinical Trial News and Research

RSS

Poor mental health can lead to heart problems and death in dialysis patients

Dialysis patients whose mental health deteriorates over time have an increased risk of developing heart problems and dying prematurely, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

6 Apr 2012

Tonix completes TNX-102 pharmacokinetic study on fibromyalgia syndrome

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system completed a pharmacokinetic (PK) study of the first formulation of its lead drug, TNX-102, for the treatment of fibromyalgia syndrome.

6 Apr 2012

Sucampo announces positive results from lubiprostone phase 3 trial on OBD

Sucampo Pharmaceuticals, Inc. today announced positive top-line results from an open-label phase 3 clinical trial designed to evaluate the long-term safety and efficacy of lubiprostone in opioid-induced bowel dysfunction (OBD) patients with chronic, non-cancer-related pain.

6 Apr 2012

Vaccine injections given directly into pancreatic cancer tumors associated with stable disease

Research from The Cancer Institute of New Jersey (CINJ) shows that a series of vaccine injections given directly into a pancreatic cancer tumor is shown to be associated with stable disease in patients who are not candidates for surgery.

5 Apr 2012

Belagenpumatucel-L improves survival for patients with stage 3B/4 NSCLC

Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine.

5 Apr 2012

Results from Abbott’s multiple interferon-free Phase 2 HCV studies to be presented at ILC 2012

Abbott will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.

5 Apr 2012

Injectable form of progestin may increase breast cancer risk in young women

The first large-scale U.S.-based study to evaluate the link between an injectable form of progestin-only birth control and breast cancer risk in young women has found that recent use of a year or more doubles the risk.

5 Apr 2012

Ventria completes VEN100 phase 2 trial on antibiotic-associated diarrhea

Ventria Bioscience has announced the successful completion of a phase 2 clinical trial of its lead therapeutic candidate, VEN100. The study was conducted by a team of investigators from the Department of Epidemiology, Division of Infectious Diseases, and Division of Geriatric Medicine at Johns Hopkins University.

5 Apr 2012

Cedars-Sinai Heart Institute performs most adult heart transplants of any U.S. medical center

For the second year in a row, the Cedars-Sinai Heart Institute and Comprehensive Transplant Center performed the most adult heart transplants of any U.S. medical center, according to government statistics.

4 Apr 2012

First study to evaluate treatment based on molecular profiling of advanced pancreatic cancer

The feasibility of selecting treatment based on individual molecular characteristics was demonstrated in a first-of-its kind pancreatic cancer clinical trial reported today by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

4 Apr 2012

Gamma-linoleic acid can inhibit growth of pancreatic cancer cells

The dietary supplement gamma-linoleic acid can inhibit the growth of a subset of pancreatic cancer cells and selectively promote cancer cell death in mice, a Mayo Clinic study has found.

4 Apr 2012

Combination of carboplatin, paclitaxel and RT3D shows promise against head and neck cancer

A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published in Clinical Cancer Research.

4 Apr 2012

Amgen, UCB commence CDP7851/AMG 785 Phase 3 trial in postmenopausal osteoporosis

UCB and Amgen announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis.

4 Apr 2012

Combination of gemcitabine and TH-302 improves survival in advanced pancreatic cancer

The combination of the novel drug TH-302 with the standard drug gemcitabine has shown early signs of delaying the worsening of cancer in patients with advanced pancreatic cancer, a Mayo Clinic-led study has found.

4 Apr 2012

Navidea announces FDA extension of Lymphoseek PDUFA date by three months

Navidea Biopharmaceuticals, Inc. today announced that yesterday it received notification from the United States Food and Drug Administration (FDA) that the Prescription Drug User Fee Act (PDUFA) date for 99m-Tc-Tilmanocept, has been modified to September 10, 2012, a 90-day extension from the initial PDUFA date of June 10th.

4 Apr 2012

Dohmen announces acquisition of BioSoteria

CEO Cynthia (Dohmen) LaConte announced today that the Dohmen Company has acquired BioSoteria, a leading provider of drug safety and risk management services to the biopharmaceutical industry.

4 Apr 2012

Bio-Path 2011 net loss increases to $2,363,344

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the year ended December 31, 2011.

4 Apr 2012

Moderate caloric intake may reduce risk of obesity in low-birth weight offspring

Babies who are born small have a tendency to put on weight during childhood and adolescence if allowed free access to calories. However, a new animal model study at UCLA found when small babies were placed on a diet of moderately regulated calories during infancy, the propensity of becoming obese decreased.

3 Apr 2012

New data demonstrates anti-cancer activities of Oncoprex

New data demonstrating the anti-cancer activities of Oncoprex were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, IL. The study, "Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1 nanoparticles in LKB1 mutant NSCLC" (Meng J, Lara-Guerra H, Ji L, Roth JA) is authored by a team of investigators from The University of Texas MD Anderson Cancer Center.

3 Apr 2012

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Keryx Biopharmaceuticals, Inc. reported today that the Phase 3 "X-PECT" clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.

3 Apr 2012

Clinical Trial News and Research

Poor mental health can lead to heart problems and death in dialysis patients

Tonix completes TNX-102 pharmacokinetic study on fibromyalgia syndrome

Sucampo announces positive results from lubiprostone phase 3 trial on OBD

Vaccine injections given directly into pancreatic cancer tumors associated with stable disease

Belagenpumatucel-L improves survival for patients with stage 3B/4 NSCLC

Results from Abbott’s multiple interferon-free Phase 2 HCV studies to be presented at ILC 2012

Injectable form of progestin may increase breast cancer risk in young women

Ventria completes VEN100 phase 2 trial on antibiotic-associated diarrhea

Cedars-Sinai Heart Institute performs most adult heart transplants of any U.S. medical center

First study to evaluate treatment based on molecular profiling of advanced pancreatic cancer

Gamma-linoleic acid can inhibit growth of pancreatic cancer cells

Combination of carboplatin, paclitaxel and RT3D shows promise against head and neck cancer

Amgen, UCB commence CDP7851/AMG 785 Phase 3 trial in postmenopausal osteoporosis

Combination of gemcitabine and TH-302 improves survival in advanced pancreatic cancer

Navidea announces FDA extension of Lymphoseek PDUFA date by three months

Dohmen announces acquisition of BioSoteria

Bio-Path 2011 net loss increases to $2,363,344

Moderate caloric intake may reduce risk of obesity in low-birth weight offspring

New data demonstrates anti-cancer activities of Oncoprex

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer